Drug evaluation: ADI-PEG-20 - A PEGylated arginine deiminase for arginine-auxotrophic cancers
Journal
Current opinion in molecular therapeutics
Journal Volume
8
Journal Issue
3
Pages
240
Date Issued
2006-06
Author(s)
Shen, Wei-Chiang
Abstract
Pheonix is developing ADI-PEG-20, a PEGylated arginine deiminase for the potential treatment of hepatocellular carcinoma, for which the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products have granted the drug Orphan Drug status, and melanoma, for which the FDA has also awarded ADI-PEG-20 Orphan Drug status. ADI-PEG-20 is also being investigated for the potential treatment of influenza virus infection and hepatitis C virus infection.
Type
journal article